Real-World Medication Adherence Trajectories to Nintedanib among Idiopathic Pulmonary Fibrosis Patients

Study identification

• EU PAS number:
  EUPAS42653
• Study ID:
  42912
• Official title and acronym:
  Real-World Medication Adherence Trajectories to Nintedanib among Idiopathic Pulmonary Fibrosis Patients
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This is a non-interventional cohort study using existing administrative data from the U.S. Medicare program. This study has two objectives: - Identification of adherence trajectories of nintedanib among Idiopathic Pulmonary Fibrosis (IPF) patients. - Understanding characteristics of patients within each nintedanib adherence trajectory among IPF patients.
• Study status:
  Planned

Research institutions and networks

Institutions

Medicus Economics

Study timelines

Date when funding contract was signed

Planned: 28/04/2021

Actual: 28/04/2021

Study start date

Planned: 23/08/2021

Data analysis start date

Planned: 23/08/2021

Date of final study report

Planned: 31/12/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only